The primary clinical question was to differentiate the risk-benefit ratio of postmenopausal estrogen therapy (ET) and estrogen-progestogen therapy (EPT) for both disease prevention and treatment of specific menopause-related symptoms.
This position statement focuses on the use of government-approved prescription ET/EPT products available in the United States and Canada, not custom ET/EPT preparations, selective estrogen-receptor modulators (SERMs), or hormones available without a prescription (including phytoestrogens).
The position statement was reviewed and approved by the NAMS 2003 NAMS -2004 Board of Trustees.
A list of the most current references regarding HT use is listed at the end of this report. The level of evidence indicated for each study is based on a grading system that evaluates the scientific rigor of the study design, as developed by the US Preventive Services Task Force. A synopsis of the levels is presented at the end of the reference list.
Introductory Comments
Because of absence of direct evidence in many circumstances, the Panel took into account all the variables in attempting to reach a general consensus on the current evidence-based role of ET/EPT use through the menopause transition and beyond. The ultimate purpose was to provide a direction for the current best practice of medicine. The recommendations that follow thus fall into two distinct categories, namely, those where there was a Panel consensus and those where consensus could not be reached.
Further, in developing recommendations, the Panel recognized that a woman's willingness to accept certain risks of ET/EPT will vary depending upon her individual situation such as when therapy is used to treat existing symptoms as opposed to long-term use to prevent a future problem that may or may not occur. Moreover, recognition had to be given to the fact that incidence of disease outcomes is also dependent on age. That is, ET/EPT is more likely to be acceptable for symptom reduction when therapy is planned to be short-term in a population that is younger with lower prevalence of risk outcomes. In contrast, the absolute risks of either use in older women or long-term therapy may make ET/EPT less acceptable. Moreover, premature hypoestrogenism (premature menopause, premature oophorectomy, or hypothalamic amenorrhea) may be associated with an increased risk of osteoporosis and cardiovascular disease based on epidemiologic observational studies. It therefore cannot be assumed that benefits and risks apply to all age ranges and all durations of therapy. All of these issues had to be taken into consideration by the Panel when developing its recommendations.
The Panel also recognized that a significant contributor to the confusion regarding the appropriate use of hormones after menopause is the actual time of onset of HT in relation to menopause (final menstrual period). There is a real difference between perimenopausal initiation for symptom relief and initiation of systemic NAMS POSITION STATEMENT Menopause, Vol. 11, No. 6, 2004 
590

R E T I R E D
HT several years beyond menopause for non-symptom-related reasons. Moreover, a deficiency of randomized prospective study data was noted on the consequences of long-term use of HT on long-term disease outcomes when prescribed for symptom management.
The Panel was also faced, as so often happens in clinical practice, with the dilemma of defining and measuring the likely level of individual risk and its context in clinical decision making. Significant confusion has resulted from caregivers, researchers, and the media misinterpreting terms such as relative risk, absolute risk, or number needed to treat. Panelists recognized the confusion that can arise when discussing risk. Key risk-related definitions are as follows:
• Rate -The number of events per number of individuals per time interval. Example: 44 per 10,000 per year • Relative Risk (RR) -Incidence in exposed divided by incidence in unexposed. Example: (44 per 10,000 per year) divided by (22 per 10,000 per year) = 2.0 • Attributable Risk (AR) -Incidence in exposed minus incidence in unexposed. Example: (44 per 10,000 per year) minus (22 per 10,000 per year) = 22 per 10,000 per year • Number Needed to Treat (NNT) -Number of individuals who must be treated with an intervention for a specific period of time to prevent 1 bad outcome or result in 1 good outcome. Example: 1 divided by (incidence in exposed minus incidence in unexposed) = 1 divided by 0.0022 = 454
To many women, and even to health professionals, these numbers are often difficult to place in practical perspective. In recognition of this problem, the World Health Organization convened a panel of experts to develop standardized nomenclature for the description of risk for adverse events. The Council for International Organizations of Medical Sciences (CIOMS) task force released its report in 1998, providing a strict form of risk categorization to assist healthcare professionals and the public when interpreting risk. In this context, risks are considered as follows:
• Յ1/1,000 = rare • Յ1/10,000 = very rare The decision to use long-term HT for prevention of disease or enhancement of quality of life is in part a lifestyle choice, and needs to be considered both in the context of risk versus benefit of the HT itself, as well as in comparison to other therapies or lifestyle choices. Another effective way to present risk is to consider the known risk in comparison with other risks of other frequently used medications. Here a good example is the risk that can be attributable to aspirin use. Aspirin utilized for myocardial infarction (MI) prophylaxis is associated with an absolute increase in the risk of hemorrhagic stroke of 12/10,000 individuals. But benefit is considered to outweigh the risks with an absolute risk reduction of 137 MIs per 10,000, and 39 ischemic strokes per 10,000.
Many large randomized controlled trials (RCTs) and observational studies of postmenopausal hormonal therapies have been published in recent years. The Panel recognized that no trial is perfect, and no single trial should be used to make public health recommendations. Evidence-based medicine implies that recommendations should be limited only to the women for whom the studies are relevant. While this is ideal in principle, it is impossible in practice, given that there will never be adequate RCTs covering all populations, eventualities, drugs, and regimens. The practice of medicine is ultimately based on the interpretation at any one time of the entire body of evidence currently available.
Although the majority opinion was that it is not possible to extrapolate conclusions from the study of one compound, dose, and route of administration directly to another, in the absence of specific safety and efficacy evidence for any one specific compound, estrogens and progestogens must be considered as specific drug classes for purposes of therapeutic indications. The Panel thus acknowledged that estrogen and progesterone agonists share some common features and effects, and the only way to establish definitively the net clinical outcome for any given agent (alone or in combination) is through randomized clinical trials. In the absence of clinical trial data for each estrogen and progestogen, the clinical trial results for one agent probably should be generalized to all agents within the same family, especially with regard to adverse effects. Where data suggest differences, this will be reported in the consensus statements.
The same proviso also needs to be recognized with regard to dose, when a different dose of the same compound is reported in previous randomized controlled trials. In the WHI, for example, the dose of conjugated equine estrogens (CEE) was 0.625 mg per day, and currently lower doses are being prescribed in clinical practice, particularly for new starters.
Another area of confusion in clinical practice is the utilization of so-called "bioidentical hormones." As a NAMS POSITION STATEMENT Menopause, Vol. 11, No. 6, 2004 591 
result of concerns about safety issues with use of traditional HT, there is escalating utilization of alternatives to pharmaceutical dosage forms of estrogens and/or progestogens, including hormonal substances prepared in unique individualized dosage forms as gels, suppositories, sublingual tablets, oral tablets, etc. The scientific evidence for these forms of usage was also reviewed and it was concluded that the same proviso applies, namely, that in the absence of specific safety and efficacy data for any specific product, the generalized risk and benefit data will apply.
The Panel acknowledged that the potential absolute risks published thus far regarding ET/EPT are small, particularly for the ET arm of the WHI which provided evidence of considerable safety for 0.625 mg of CEE per day. The risks in the EPT arm were small and by CIOMS criteria rare, as are the likely benefits. For women younger than 50 or those at low risk for coronary heart disease (CHD), stroke, osteoporosis, breast cancer, or colon cancer, the absolute risk or benefit from ET or EPT is likely to be even smaller than demonstrated in WHI, although the relative risk may be similar. An individual risk profile is essential for every woman contemplating any regimen of EPT or ET. Women should be informed of known risks.
Finally, the Panel concluded that there is always a need to recognize that even in the absence of HT use, there is risk of development of all the diseases under consideration. In randomized controlled studies, that background inherent risk is represented by the rate of occurrence of the problem in the placebo group. Differences in relative risk between active drug and placebo can result from increased or decreased incidence of the event in either study group.
Recommendations for Clinical Practice: Areas of Consensus
The Panel agreed on the following clinical recommendations for postmenopausal hormone therapy.
• A strong recommendation was made for uniform and consistent terminology for menopause-related therapies, as indicated below:
ET estrogen therapy EPT combined estrogen-progestogen therapy HT hormone therapy (encompassing both ET and EPT) CC-EPT continuous-combined estrogen-progestogen therapy (daily administration of both estrogen and progestogen)
CS-EPT continuous-sequential estrogenprogestogen therapy (estrogen daily, with progestogen added on a set sequence) systemic ET/EPT preparations of ET or EPT that have a systemic, not solely vaginal, effect local ET preparations of ET that have a predominantly vaginal, not systemic, effect progestogen encompassing both progesterone and progestin
• Treatment of moderate to severe menopause symptoms (ie, vasomotor symptoms, sleep disruption from vasomotor symptoms) remains the primary indication for systemic ET and EPT. Every systemic ET/EPT product is government-approved for this indication.
• Every systemic and local ET/EPT product is government-approved for treating moderate to severe symptoms of vulvar and vaginal atrophy, such as vaginal dryness, dyspareunia, and atrophic vaginitis. When hormones are considered solely for this indication, local ET is generally recommended.
• The primary menopause-related indication for progestogen use is endometrial protection from unopposed ET. For all women with an intact uterus who are using estrogen therapy, clinicians are advised to prescribe adequate progestogen, in either a CC-EPT or CS-EPT regimen. Postmenopausal women without a uterus should not be prescribed a progestogen.
• Some women with an intact uterus who choose EPT may experience undesirable side effects from the progestogen component. However, there is insufficient evidence regarding endometrial safety to recommend use of long-cycle progestogen (ie, progestogen every 3-6 months for 12-14 days), a progestin-containing intrauterine device, or lowdose estrogen without progestogen as an alternative to standard EPT regimens. If utilizing any of these approaches, close surveillance of the endometrium is recommended, pending more definitive research. There are encouraging data on the efficacy of lower-dose therapies with reduction of side effects.
• ET and EPT did not reduce coronary heart disease (CHD) incidence in the WHI study. The role of ET/EPT in primary prevention of coronary heart disease (CHD) remains unclear when considered for peri-and early postmenopausal women if started early and continued for a number of years, Menopause, Vol. 11, No. 6, 2004 • Data from studies such as the WHI and the Heart and Estrogen/progestin Replacement Study (HERS) should not necessarily be extrapolated to symptomatic postmenopausal women younger than 50 years of age who initiate HT as these women were not studied in these trials. WHI and HERS involved predominantly asymptomatic postmenopausal women aged 50 years and over (with mean ages of 63 and 67, respectively), the majority of whom were 10 years or more beyond menopause, and HERS was conducted solely among women with known coronary artery disease. The data should not be extrapolated to women experiencing premature menopause (Յ 40 years of age) and initiating HT at that time.
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• Premature menopause and premature ovarian failure are conditions associated with earlier onset of osteoporosis and CHD, but there are no clear data as to whether ET or EPT will reduce morbidity or mortality from these conditions. The benefit-risk ratio may be more favorable for younger women who initiate therapy at an early age.
• Use of ET and EPT should be consistent with treatment goals, benefits, and risks for the individual woman, taking into account symptoms and domains (eg, sexuality, sleep) that may have an impact on quality of life.
• Lower-than-standard doses of ET and EPT should be considered (ie, daily doses of 0.3 mg oral conjugated estrogens, 0.25-0.5 mg oral micronized 17␤- Menopause, Vol. 11, No. 6, 2004 Other specific examinations, such as bone densitometry, should be considered on a case-by-case basis.
• The Panel concluded that with regard to duration of use, a general guiding principle should be for the lowest effective dose and time consistent with treatment goals. The Panel recognized that symptoms can recur when therapy is discontinued, independent of age and duration of ET/EPT use. The Panel agreed that the decision to continue HT should be individualized based on severity of symptoms, current risk-benefit considerations, and that the woman in consultation with her healthcare provider believes that continuation of therapy is warranted.
• The Panel concluded that an improvement in health-related quality of life (HQOL) can result through decreased menopause symptoms and possible elevation of mood that leads to a feeling of well-being. There is a lack of consensus on the impact of HT on overall quality of life (QOL) and HQOL in asymptomatic women. In part this is due to a lack of agreement regarding how best to obtain an appropriate evaluation of QOL in women after menopause, including the domains to be incorporated into any survey instruments. There is consensus that validated instruments for determining the impact of HT, or indeed any menopause-related therapy, on both overall QOL and HQOL should be incorporated into future studies.
• The Panel recognized that specific compounds, dose, and route of administration may have different outcomes. Nonetheless, in the absence of clinical trial data for each specific product, the clinical trial results for one agent should be generalized to all agents within the same family. This proviso also applies to the so-called bioidentical products.
Areas Where Insufficient or Conflicting Evidence Precludes Consensus
The Panel could not reach consensus on the following issues:
• Is HT associated with early risk of CHD? Panelists were divided on the issue as to whether there is definitive evidence for early increased risk of CHD with HT. For women similar to participants in the EPT arm of WHI (average age 63 years; range from 50 to 79 years), the WHI data are the best estimate of early harm from EPT. The WHI demonstrated that EPT may increase the risk of CHD during the first year of hormone use among generally healthy postmenopausal women in whom HT is initiated up to 20 or more years after menopause. The attributable risk in this instance, under the CIOMS classification, falls into the rare category. In addition, in HERS the increased risk of CHD in the first year due to EPT use was not observed in women who NAMS POSITION STATEMENT Menopause, Vol. 11, No. 6, 2004 were concomitantly using statin therapy. There is also evidence that early harm within the first year of use may not pertain to healthy postmenopausal women using ET/EPT for menopause symptom management. Increased risk of CHD in the first year was not observed in the ET arm of the WHI or any other ET-only study.
• Should women who are doing well on long-term HT discontinue? The Panelists were divided in opinion as to whether women on well established long-term therapy should be advised to discontinue at a specific duration of therapy. No recommendation is made, but there is agreement that the risks and benefits must be discussed on an individualized basis.
• Is there a best way to discontinue HT? When a decision is made to discontinue therapy, Panelists were divided in their recommendations regarding abrupt therapy cessation versus tapering the dose. Past history of severe symptoms may favor tapering, but no specific protocols could be recommended. Some gradually decrease the dose, while others lengthen the time between doses. Matrix transdermal HT patches can be trimmed to provide smaller doses. Current data are inadequate to suggest that one method is better than the other.
• Does a continuous-combined EPT regimen (CC-EPT) have an effect different from continuous estrogen with sequential progestogen (CS-EPT)?
There are some indications that continuous progestogen in the dosages administered in studies such as WHI and HERS may be related to these trials' adverse breast cancer and cardiovascular outcomes, but conflicting data preclude a consensus.
Need for Future Research
On the basis of this review, the Panelists identified the following areas requiring further research.
Further study of the positive and negative effects of hormone therapy and the mechanisms by which they occur.
• Timing of initiation of HT relative to menopause with regard to cardiovascular, cognitive, and other health outcomes.
• Compare different formulations, regimens, and doses of both estrogens and progestogens.
• Determine whether HT should be based on manipulating endogenous hormone levels to premenopausal physiological concentrations rather than traditional single dosing for all women.
• Effects of endogenous levels of estradiol and/or estrone on benefit and/or risk.
• Determine whether the combination of ET/EPT and statin therapy could result in amelioration of potential CHD risks while preserving and possibly enhancing the benefits of HT.
• Long-term benefits/risks of ET and EPT, including different preparations, lower than standard dosages, and different regimens and routes of administration other than oral CEE and oral medroxyprogesterone acetate.
• Cause for the probable increase in stroke with ET, and for probable increased stroke, CHD, and breast cancer with EPT, in order to better understand the pathophysiology of these events, identify potential new treatments and ways to prevent their occurrence, and to identify a subgroup for whom HT would be less toxic.
• How to factor other health outcomes including QOL issues into the composite benefit-risk profile for ET/EPT.
• Health outcomes for HT over the long term (greater than 10 years).
• The benefit-risk profile of CS-EPT compared with CC-EPT or other HT regimens.
• Endometrial effects from alternatives to standard progestogen regimens, such as a progestinreleasing intrauterine device or long-cycle progestogen regimens.
• Long-term effects of ET/EPT on Alzheimer's disease risk and other forms of dementia, particularly when therapy is initiated before age 65.
• Short-and long-term effects of ET/EPT on neuropsychiatric disorders, such as Parkinson's disease, sleep apnea, depression, and schizophrenia.
• Effects of estrogen on mood and interactions of estrogens with mood-altering drugs.
• Long-term effects of ET/EPT on primary and secondary prevention and progression of ophthalmologic disorders, such as cataract and age-related macular degeneration.
• Health outcomes with ET/EPT for women experiencing early or premature menopause.
• Health outcomes with osteoporosis drugs over the long term (>10 years).
• Role of progestogens (eg, type, regimen) in breast cancer and cardiovascular risk.
• Efficacy of nonpharmacologic methods of managing hot flashes.
• The benefit-risk profile associated with an abrupt versus a tapering discontinuation of HT regimens, including impact on bone density in the first 2 or 3 years after termination. Menopause, Vol. 11, No. 6, 2004 595
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• Effects of HT discontinuation on health outcomes influenced by HT.
• Role of estrogen and progestogen in postmenopausal women with underlying disease such as diabetes mellitus and hypertension to evaluate the effects of HT on the adverse events associated with the disease itself.
• How women can best be identified for risk of deep venous thrombosis and pulmonary embolism, as well as hypercoagulability responsiveness to estrogens in general.
• Identification of subgroups of women for whom ET or EPT might be beneficial with regard to cardiovascular, cognitive, and overall health outcomes.
Further study of the natural history of the menopause transition.
• Incidence and course of CHD, breast cancer, dementia, and other health outcomes in women experiencing early or premature menopause.
• Stricter evaluation of domains of QOL through the menopause transition.
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